These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522 [TBL] [Abstract][Full Text] [Related]
49. Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma. Sawazaki A; Sugimori C; Yamaguchi M; Nakao S Transfus Apher Sci; 2023 Jun; 62(3):103649. PubMed ID: 36739175 [TBL] [Abstract][Full Text] [Related]
50. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts. Holmberg LA; Linenberger M; Connelly-Smith L Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104 [TBL] [Abstract][Full Text] [Related]
51. Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Jackson GH; Davies FE; Pawlyn C; Cairns DA; Striha A; Collett C; Waterhouse A; Jones JR; Kishore B; Garg M; Williams CD; Karunanithi K; Lindsay J; Allotey D; Shafeek S; Jenner MW; Cook G; Russell NH; Kaiser MF; Drayson MT; Owen RG; Gregory WM; Morgan GJ; Clinical Studies Group UNHO Haematologica; 2021 Jul; 106(7):1957-1967. PubMed ID: 32499244 [TBL] [Abstract][Full Text] [Related]
52. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. Moreau P; Hebraud B; Facon T; Leleu X; Hulin C; Hashim M; Hu Y; Caillot D; Benboubker L; Zweegman S; Merz M; Weisel K; Salwender H; Mai EK; Goldschmidt H; Bertsch U; Vanquickelberghe V; Kampfenkel T; Boer C; Krotneva S; Proskorovsky I; He J; Lam A; Lee C; Cote S; Sonneveld P Immunotherapy; 2021 Feb; 13(2):143-154. PubMed ID: 33228440 [No Abstract] [Full Text] [Related]
53. Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. Tuchman SA; Bacon WA; Huang LW; Long G; Rizzieri D; Horwitz M; Chute JP; Sullivan K; Morris Engemann A; Yopp A; Li Z; Corbet K; Chao N; Gasparetto C J Clin Apher; 2015 Jun; 30(3):176-82. PubMed ID: 25293363 [TBL] [Abstract][Full Text] [Related]
54. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma. He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297 [TBL] [Abstract][Full Text] [Related]
55. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Johnsrud A; Ladha A; Muffly L; Shiraz P; Goldstein G; Osgood V; Shizuru JA; Johnston L; Arai S; Weng WK; Lowsky R; Rezvani AR; Meyer EH; Frank MJ; Negrin RS; Miklos DB; Sidana S Transplant Cell Ther; 2021 Jul; 27(7):590.e1-590.e8. PubMed ID: 33915323 [TBL] [Abstract][Full Text] [Related]
56. [Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma]. Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gal'tseva IV; Kuz'mina LA; Akhundova FM; Kalinin NN; Gretsov EM; Parovichnikova EN; Savchenko VG Ter Arkh; 2012; 84(7):35-41. PubMed ID: 23038970 [TBL] [Abstract][Full Text] [Related]
57. [Efficacy and safety of lenalidomide combined with bortezomib and dexamethasone induction therapy in newly diagnosed patients with multiple myeloma]. Yao WQ; Yan LZ; Shang JJ; Jin S; Shi XL; Yan S; Yan Z; Wang QQ; Fu CC; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):657-662. PubMed ID: 36709150 [No Abstract] [Full Text] [Related]
58. Mobilisation of tumour cells along with CD34+ cells to peripheral blood in multiple myeloma. Knudsen LM; Rasmussen T; Nikolaisen K; Johnsen HE Eur J Haematol; 2001; 67(5-6):289-95. PubMed ID: 11872076 [TBL] [Abstract][Full Text] [Related]
59. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma]. Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691 [TBL] [Abstract][Full Text] [Related]
60. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]